Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer Clinical Trials in Toronto, Ontario

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.